Sysmex and bioMérieux Agreed to Dissolve the Joint Venture Sysmex bioMérieux Co., Ltd.
27 Juillet 2017 - 8:00AM
Business Wire
Regulatory News:
Sysmex Corporation (“Sysmex”) and bioMérieux S.A. (“bioMérieux”)
(Paris:BIM) announce they have agreed to transfer all of Sysmex’
holdings in Sysmex bioMérieux Co., Ltd. (Tokyo, Japan) to
bioMérieux thereby dissolving the joint venture created by and
between the two companies in 2008 with the goal of bringing
together bioMérieux’s innovative business and Sysmex’ expertise of
the Japanese market.
1. Agreement on the MatterIn discussions
between Sysmex and bioMérieux, an agreement was reached by which
Sysmex will transfer all of its holdings in Sysmex bioMérieux (34%
of shares) to bioMérieux. As a consequence of the dissolution, the
distribution agreement relating to the distribution of bioMérieux
products in Japan between Sysmex and Sysmex bioMérieux will also
terminate as of October 31, 2017. Sysmex will continue to provide
customer service in Japan for bioMérieux products until March 31,
2018. Subsequently, bioMérieux will build its commercial structure
in Japan for the long term to take over the activities previously
led by Sysmex.
2. Overview of the Joint Venture(1) Name:
Sysmex bioMérieux Co., Ltd.(2) Location: 1-2-2 Osaki, Shinagawa-ku,
Tokyo(3) Representative: Kentaro Yoshida(4) Business: Manufacture
and sale of in vitro diagnostic reagents and medicalinstruments
related to microbes, genes and immunochemistry(5) Capital: 480
million JPY(6) Ownership: bioMérieux S.A. 66.0%Sysmex Corporation
34.0%(7) Established: October 4, 1988
3. Share Transfer Date October 31, 2017
(scheduled)
About Sysmex
Sysmex Corporation is a world leader in clinical laboratory
systemization and solutions, including laboratory diagnostics,
laboratory automation and clinical information systems. Serving
customers for more than 40 years, Sysmex focuses on technological
leadership in diagnostic science and information tools that make a
difference in the health of people worldwide.
The company is also exploring emerging opportunities in the life
science field. Its R&D efforts focus on the development of
high-value-added testing and diagnostic technologies that are
innovative, original and optimize individual health. Sysmex also
seeks to leverage its state-of-the-art technologies for cell, gene
and protein analysis.
The company, headquartered in Kobe, Japan, has subsidiaries in
North America, Latin America, Europe, the Middle East, Africa,
China and Asia Pacific and employs about 8,000 employees worldwide.
Sysmex Corporation is listed in the top tier of the Tokyo Stock
Exchange. For more information about Sysmex Corporation and its
affiliate companies, please visit http://www.sysmex.co.jp/en/.
About bioMérieux
Pioneering Diagnostics
A world leader in the field of in vitro diagnostics for more
than 50 years, bioMérieux is present in more than 150 countries
through 42 subsidiaries and a large network of distributors. In
2016, revenues reached €2,103 million, with more than 90% of
international sales.
bioMérieux provides diagnostic solutions (reagents, instruments,
software) which determine the source of disease and contamination
to improve patient health and ensure consumer safety. Its products
are mainly used for diagnosing infectious diseases. They are also
used for detecting microorganisms in agri-food, pharmaceutical and
cosmetic products.
bioMérieux is listed on the Euronext Paris market (Symbol: BIM –
ISIN: FR0010096479).
Corporate website: www.biomerieux.comInvestor website:
www.biomerieux-finance.com
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170726006528/en/
SysmexInvestor Relations & Corporate
CommunicationsJohji Hayashi, +81 (0)78 265
0508info@sysmex.co.jporbioMérieuxInvestor
RelationsSylvain Morgeau, + 33 (0)4 78 87 22
37investor.relations@biomerieux.comorMedia RelationsAurore
Sergeant, + 33 4 78 87 20 53media@biomerieux.comorLaurence
Heilbronn, + 33 1 53 70 74 64lheilbronn@image7.frorClaire Doligez,
+33 (0)1 53 70 74 48cdoligez@image7.fr
Biomerieux (EU:BIM)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Biomerieux (EU:BIM)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024